drugset / Trial / NCT06871046
Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions
Phase 3
Completed
221 enrolled
Teikoku Seiyaku Co., Ltd.
CRM Biometrics GmbH · collabClinSearch · collabHWI pharma services GmbH · collabSocraMetrics GmbH · collabSocraTec R&D GmbH · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label, multi-centric clinical trial to evaluate the safety and efficacy of TK-254RX in patients with contusions. The primary objective of this study is to assess the safety of TK-254RX. Secondly objective is to evaluate the efficacy of contusions and adhesion of TK-254RX.
Timeline
- Start
- 2025-02-20
- Primary completion
- 2025-09-22
- Completion
- 2025-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Esflurbiprofen | Small molecule | 165 mg | Topical |
Indications
No indication recorded.